Xeris Biopharma Holdings (XERS) EPS (Basic) Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | -1,388.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,388.38% |
| Mar 31, 2026 | 121.66% |
| Dec 31, 2025 | 298.28% |
| Sep 30, 2025 | 103.59% |
| Jun 30, 2025 | 88.05% |
| Mar 31, 2025 | 55.22% |
| Dec 31, 2024 | 64.18% |
| Sep 30, 2024 | -19.64% |
| Jun 30, 2024 | 29.99% |
| Mar 31, 2024 | -10.04% |
| Dec 31, 2023 | -2.02% |
| Sep 30, 2023 | 45.02% |
| Jun 30, 2023 | 25.22% |
| Mar 31, 2023 | 50.84% |
| Dec 31, 2022 | 85.17% |
| Sep 30, 2022 | 58.94% |
| Jun 30, 2022 | 53.40% |
| Mar 31, 2022 | 16.94% |
| Dec 31, 2021 | -25.39% |
| Sep 30, 2021 | -12.80% |